Cariprazine for Acute and Maintenance Treatment of Adults with Schizophrenia: An Evidence-Based Review and Place in Therapy by Citrome, Leslie L
Touro Scholar 
NYMC Faculty Publications Faculty 
10-1-2018 
Cariprazine for Acute and Maintenance Treatment of Adults with 
Schizophrenia: An Evidence-Based Review and Place in Therapy 
Leslie L. Citrome 
New York Medical College 
Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Citrome, L. L. (2018). Cariprazine for Acute and Maintenance Treatment of Adults with Schizophrenia: An 
Evidence-Based Review and Place in Therapy. Neuropsychiatric Disease and Treatment, 14, 2563-2577. 
https://doi.org/10.2147/NDT.S159704 
This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for 
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, 
please contact touro.scholar@touro.edu. 
© 2018 Citrome. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php  
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neuropsychiatric Disease and Treatment 2018:14 2563–2577
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2563
R e v i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/NDT.S159704
Cariprazine for acute and maintenance treatment 
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review and place in therapy
Leslie Citrome
Department of Psychiatry and 
Behavioral Sciences, New York 
Medical College, valhalla, NY, USA
Abstract: Cariprazine is an oral antipsychotic approved in the US and EU for the treatment 





-receptor partial agonist, with tenfold higher affinity for D
3
 receptors than for D
2
 
receptors. Cariprazine is metabolized in two steps by CYP3A4 to didesmethyl-cariprazine 
(DDCAR). DDCAR has a long half-life of 1–3 weeks and is the predominant circulating active 
moiety. Efficacy and safety in persons with acute schizophrenia were assessed in four similarly 
designed, short-term, randomized, placebo-controlled clinical trials in nonelderly adults, with 
three studies considered positive and yielding a number needed to treat vs placebo for response 
(change from baseline $30% in Positive and Negative Syndrome Scale total score) of ten for 
the approved dose range of cariprazine 1.5–6 mg/day. The most common adverse reactions were 
extrapyramidal symptoms (15% and 19% for 1.5–3 and 4.5–6 mg/day, respectively, vs 8% for 
placebo) and akathisia (9% and 12.5% for 1.5–3 and 4.5–6 mg/day, respectively, vs 4% for 
placebo). For the approved dose range, rates of discontinuation because of an adverse event were 
lower overall for patients receiving cariprazine vs placebo (9% vs 12%). Weight and metabolic 
profile appear favorable. Cariprazine does not increase prolactin levels or prolong the electro-
cardiographic QT interval. Cariprazine has also been found to be effective for the maintenance 
treatment of schizophrenia by delaying time to relapse when compared with placebo (HR 0.45). 
A 26-week randomized clinical trial evidenced superiority of cariprazine over risperidone for 
the treatment of predominantly negative symptoms in patients with schizophrenia. Cariprazine 
is also approved in the US for the acute treatment of manic or mixed episodes associated with 
bipolar I disorder in adults and is being studied for the treatment of bipolar I depression and 
major depressive disorder.
Keywords: cariprazine, didesmethyl-cariprazine, dopamine-receptor partial agonist, schizo-
phrenia, dopamine D3 receptor
Introduction
Schizophrenia, a relatively common and chronic psychotic disorder, is notable for its 
marked heterogeneity in disease course and response to treatment, as well as differences 
among currently available psychopharmacological interventions.1–3 New medications 
are welcomed, in the hope that they can address the shortcomings of prior drugs in 
terms of both therapeutic targets4 and tolerability profile.5
Cariprazine is an antipsychotic medication that received initial approval by the US 
Food and Drug Administration (FDA) in 20156 and approval by the European Medicines 
Agency in 2017.7 Although cariprazine is the third dopamine-receptor partial agonist 
antipsychotic to become generally available, it differs from the other two, aripiprazole 
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and brexpiprazole, in several respects.8,9 This paper reviews 
the pharmacology, mode of action, and pharmacokinetics of 
cariprazine and the published peer-reviewed evidence sup-
porting its use in persons with schizophrenia.
Literature search
A literature search was conducted on July 4, 2018, using 
the US National Library of Medicine’s PubMed resource. 
Other sources of information included product labeling10 
and the author’s prior published reviews.11–13 Searching for 
“cariprazine” using PubMed yielded 125 records, of which 
15 were original reports of clinical trial data in persons with 
schizophrenia,14–28 24 were medicinal chemistry or preclinical 
research reports,29–52 9 were original reports of cariprazine 
clinical trial data for disorders other than schizophrenia,53–61 
and the remainder consisted of reviews, commentaries, or 
articles that did not appear directly relevant. Three meta-
analyses were found that focused on cariprazine and included 
data for the treatment of schizophrenia.62–64
Pharmacology, mode of action, and 
pharmacokinetics of cariprazine
Current FDA-approved pharmacological interventions for 
schizophrenia focus on antagonism or partial agonism at the 
dopamine D
2
 receptor and, in the case of second-generation 
(atypical) antipsychotics, antagonism at the serotonin 5HT
2A
 
receptor.4 However, the antipsychotics differ in terms of 
their pharmacodynamic profile by secondary binding char-
acteristics at other receptors, with some of these affinities 
often being more robust (ie, associated with a lower binding 
constant or K
i
) than for dopamine D
2









agonist with tenfold higher affinity for D
3







 receptors 0.085 nM vs 0.49 nM and 
0.69 nM for the two types of D
2
 receptors assayed).10,13,30 
Intrinsic activity of cariprazine at dopamine D
2
 receptors is 
numerically lower than that for aripiprazole.33 Additional 










 receptors with high and moderate binding 
affinity (K
i
 0.58 and 18.8 nM, respectively) and moderate 
affinity for the histamine H
1
 receptor, also as an antagonist 
(K
i







 134 and 
155 nM, respectively), and no appreciable affinity has been 
noted for cholinergic muscarinic receptors (IC
50
.1,000 nM). 
The three commercially available dopamine-receptor partial 
agonists (aripiprazole, brexpiprazole, and cariprazine) have 
differing receptor-binding profiles, making them distinct 
molecular entities (see Table 2 located in reference 8).8
A substantial amount of preclinical data is available 
supporting the potential therapeutic benefit of targeting dop-
amine D
3
 receptors.32,35,36,39,44,46,47 Theoretically, antagonism at 
D
3
 autoreceptors can enhance dopaminergic neurotransmis-
sion, especially in such brain areas as the prefrontal cortex, 
where dopamine release appears to be controlled by D
3
 
receptors.66 With disinhibition of dopamine release, cortical 
circuits can be “tuned” to improve cognition, mood, and 
negative symptoms.67 In this process, acetylcholine release in 
the prefrontal cortex may be enhanced as well, which could 
also contribute to procognitive actions.66
The pharmacokinetic profile of cariprazine is markedly 
different than that of other currently marketed antipsychot-
ics. Although extensive metabolism by CYP3A4 (and to 
a lesser extent by CYP2D6) is not unusual, the ultimate 
active metabolite, didesmethyl-cariprazine (DDCAR), 
has a long half-life, described in product labeling as 1–3 
weeks.10 Therefore, DDCAR is the predominant circulating 
active moiety. Following a single dose of 1 mg cariprazine, 
DDCAR remains detectable at 8 weeks postdose. This has 
important implications in terms of dosing and interpreta-
tion of clinical trial results, which will be discussed later. 
DDCAR has an in vitro receptor-binding profile similar 
to cariprazine (K
i
 0.057 nM for dopamine D
3
 receptors 
and 1.41 and 2.64 nM for the two types of D
2
 receptors 
assayed);6,10 however, intrinsic activity at the dopamine D
2
 
receptor for DDCAR has been reported to be about half that 
for cariprazine.33
Additional details regarding the pharmacokinetic profile 
of cariprazine can be found in a report of a multicenter, 
randomized, open-label, parallel-group, fixed-dose (3, 6, or 
9 mg/day) study of 28-week duration (#4-week observation, 
12-week open-label treatment, and 12-week follow-up), 
where cariprazine was administered once daily to 38 adult 
patients with schizophrenia.18 Steady state was reached within 
1–2 weeks for cariprazine and DCAR (the intermediate active 
metabolite that gets transformed to DDCAR), 4 weeks for 
DDCAR, and 3 weeks for total active moieties. Cariprazine 
and DCAR levels decreased .90% within 1 week after the 
last dose, in contrast to DDCAR, which had decreased ~50% 
at 1 week. Total active moieties decreased ~90% within 
4 weeks. In this study, the terminal half-lives of cariprazine, 
DCAR, and DDCAR ranged 32–68, 30–38, and 314–446 
hours (~2–3 weeks), respectively. The effective half-life (cal-
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Cariprazine for the treatment of schizophrenia
approximately 1 week. Exposure was dose proportional over 
the range of 3–9 mg/day. The product label notes that mean 
concentrations of DCAR and DDCAR are approximately 
30% and 400%, respectively, of cariprazine concentrations 
by the end of 12-week treatment.10 Figure 1 illustrates the 
key points regarding concentrations of cariprazine, DCAR, 
and DDCAR over time.
Time to peak concentration of cariprazine is 3–6 hours.10,18 
Administration of a single dose of 1.5 mg cariprazine with a 
high-fat meal does not significantly affect maximum concen-
tration or area under the concentration curve of cariprazine 
or DCAR.10 Cariprazine and its major active metabolites are 
highly bound (91%–97%) to plasma proteins.10
Drug–drug interactions involving a strong CYP3A4 
inhibitor will necessitate reduction of the cariprazine dose by 
half (for patients already taking 4.5 mg/day, dosage should 
be reduced to 1.5 or 3 mg/day, and for patients taking 1.5 mg 
daily, the dosing regimen should be adjusted to every other 
day).10 When initiating cariprazine in a person already on a 
strong CYP3A4 inhibitor, the patient should be administered 
1.5 mg on days 1 and 3, with no dose administered on day 2. 
From day 4 onward, the dose should be administered at 
1.5 mg/day, then increased to a maximum dose of 3 mg/day. 
When the CYP3A4 inhibitor is withdrawn, cariprazine dos-
age may need to be increased.10 Concomitant use of carip-
razine and a CYP3A4 inducer has not been evaluated and is 
not recommended, because the net effect on the active drug 
and metabolites is unclear.10
No dosage adjustment is required in the presence of 
CYP2D6 inhibitors or in persons who are poor CYP2D6 
metabolizers.10 For patients with mild–moderate hepatic or 
renal impairment, no dosage adjustment is required. Carip-
razine has not been studied in patients with severe hepatic 
or renal impairment, and is thus not recommended for such 
patients.10 No dosage adjustment for cariprazine is required 
based on age, sex, race, or smoking status.10 Although doses 
of cariprazine #12 mg/day have been assessed in the clinical 
trials described herein, the recommended maximum dose 
is 6 mg/day, because of a dose-related increase in certain 
adverse reactions, particularly at doses .6 mg/day.10
Efficacy and safety in acute 
schizophrenia
Four similarly designed, short-term, randomized, placebo-
controlled clinical trials in nonelderly adults with acute 
exacerbations of schizophrenia have been conducted and 
published,14–17 of which three are included in section 14 of 
the product label and considered supportive of efficacy.10,15–17 
Table 1 provides an overview of all four studies. For 
consistency, statistical outcomes based on the mixed-effect 
model for repeated measures are presented for all studies, 
even though it was the primary method of analysis for only 
the two phase III studies.16,17
In the three supportive pivotal trials,15–17 the mean age of 
participants was 38 years, ~70% were male, and ~40% were 
white. Mean body-mass index was 26 kg/m2. A little more 
than 50% of subjects were in the US. The mean baseline 
Positive and Negative Syndrome Scale (PANSS) total score 
was about 97. All tested doses of cariprazine – 1.5, 3, 4.5, 6, 
3–6, and 6–9 mg/day – were superior to placebo on reduc-
tion in PANSS total score, the primary outcome measure 
for each of the trials. Patients were also assessed using the 
Clinical Global Impression – severity (CGI-S) score, which 
was the key secondary end-point measure. Cariprazine was 
consistently superior to placebo on this outcome as well. A 
pooled analysis of CGI-S scores examining shifts, such as 
from extremely or severely ill (CGI-S $5) to mildly ill or bet-
ter (CGI-S #3), demonstrated an advantage for cariprazine 
over placebo (OR 3.4, 95% CI 1.5–7.9).26 Of clinical rel-
evance are observed effect sizes for antipsychotic response, 
as defined by change from baseline $30% in PANSS total 
score.15–17 Pooling together data for the approved dose range 
of cariprazine (1.5–6 mg/day) revealed a number needed to 
treat (NNT) vs placebo of ten (95% CI 7–19);11 however, 
in one trial the NNT vs placebo for response was as robust 
as six.15 Indirect comparisons with other antipsychotics 
Figure 1 Plasma concentration at trough (mean ± SE)–time profile during and 
following 12-weeks of treatment with cariprazine 6 mg/day.
Notes: Reproduced from the product label.10 DDCAR is the predominant 
circulating moiety, representing about 70% of the total exposure. when treatment 
is discontinued, DDCAR concentrations persist longer than for cariprazine or 
DCAR.
Abbreviations: CAR, cariprazine; DDCAR, didesmethyl-cariprazine; total CAR, 
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are hampered by lack of a uniform definition for response; 
however, similar criteria used for the assessment of NNT vs 
placebo for aripiprazole and brexpiprazole (response defined 
as change from baseline $30% in PANSS total score or a 
CGI – improvement score of 1 [very much improved] or 
2 [much improved]) in similar acute studies yielded NNT 
values of eight for aripiprazole and seven for brexpiprazole, 
with overlap of 95% CIs.8 A tutorial on NNT can be found 
in a prior review.11
Cariprazine has also been evaluated post hoc for specific 
antihostility effects in patients with schizophrenia.25 Data 
were pooled from the three positive acute studies,15–17 and 
the principal outcome was mean change from baseline to 
week 6 on the PANSS hostility item. Significantly greater 
improvement in hostility was seen in favor of cariprazine-
treated patients compared with placebo-treated patients. The 
improvement associated with cariprazine appeared to be par-
tially independent of improvement in PANSS positive symp-
toms, such as hallucinations and delusions, independent of the 
presence or absence of sedation, and was greater in magnitude 
in patients with higher levels of hostility at baseline.
Two meta-analyses are available that have examined the 
efficacy of cariprazine in acute schizophrenia63,64 using the 
four studies available.14–17 In one meta-analysis,63 low and 
high ($6 mg/day) doses were tested separately, and both 
high and low cariprazine doses demonstrated superiority 
to placebo in all symptom domains (PANSS total score, 
PANSS positive, PANSS negative, PANSS response, 
Schizophrenia Quality of Life Scale – revision 4, and CGI – 
improvement). No differences were found between high 
and low doses on these measures. The standardized mean 
difference vs placebo showed a modest impact on overall 
symptoms compared with meta-analytic results for other 
antipsychotics (effects similar to lurasidone, asenapine, 
ziprasidone, and aripiprazole, but less than for risperidone, 
quetiapine, and olanzapine). The other meta-analysis64 also 
demonstrated superiority of cariprazine over placebo for 
PANSS total, PANSS positive, and PANSS negative score 
changes from baseline.
Safety and tolerability data collected during the four 
acute trials in schizophrenia included the incidence of 
spontaneously reported adverse events (briefly summarized 
in Table 1 by study), body weight, laboratory measurements, 
vital signs, electrocardiography, and movement-disorder 
scales. For cariprazine doses of 1.5–6 mg/day, rates of dis-
continuation because of an adverse event were overall lower 
for patients receiving cariprazine vs placebo (9% vs 12%).8 
As per the product label, there was no single adverse reac-
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in cariprazine-treated patients and at least twice the rate of 
placebo.10 A pooled analysis of safety and tolerability is 
available using three modal daily dose groups (ie, most fre-
quent dose taken by a patient during double-blind treatment): 
1.5–3, 4.5–6, and 9–12 mg/day.24 The overall incidence of 
treatment-emergent adverse events vs placebo was similar 
for cariprazine 1.5–3 mg/day, but higher for cariprazine 
4.5–6 and 9–12 mg/day, with a dose–response relationship 
observed for akathisia, extrapyramidal symptoms (EPS), 
and diastolic blood pressure. Regarding the latter, a shift 
from normotensive to stage I hypertension was observed 
in 2.0% of patients receiving placebo compared with 1.1%, 
2.8%, and 6.8% for patients receiving 1.5–3, 4.5–6, and 
9–12 mg/day of cariprazine, respectively. Patients in the 
modal dose .6 mg/day group showed a higher likelihood for 
weight increase, as well as higher rates of CPK and transami-
nase elevations. These observations on doses .6 mg/day 
resulted in the FDA approving a recommended dose range 
for schizophrenia of 1.5–6 mg/day.10,24
From the pooled data, mean changes in metabolic 
parameters were generally similar in cariprazine-treated 
and placebo-treated patients.24 No prolactin level increase or 
QTc value .500 ms was noted. The incidence of orthostatic 
hypotension was similar for placebo (12.3%) and caripra-
zine (13.4%). No syncopal episodes were reported. Weight 
increase with cariprazine overall was 1.1 kg compared with 
0.3 kg for placebo-treated patients. Weight increase $7% 
occurred in 9.2% of cariprazine-treated patients and 4.7% 
of placebo-treated patients at any time during double-blind 
treatment, for a calculated number needed to harm (NNH) 
vs placebo of 23 (95% CI 15–46). Within the recommended 
dose range of 1.5–6 mg/day, mean weight gain was #1 kg 
for cariprazine, and proportions with $7% increase in weight 
were 7.6% and 7.7% for the 1.5–3 and 4.5–6 mg/day groups, 
respectively, yielding a NNH vs placebo of 35 (95% CI 
18–1,248) and 34 (95% CI 18–443), respectively.
Of note, both mean weight change and shifts in 
weight $7% were larger in the 9–12 mg/day dose group, 
with a rate of 17.2% and resulting in a calculated NNH vs 
placebo of 8 (95% CI 6–15); however, there was no cor-
responding alteration in fasting triglycerides, as noted by 
a shift in rate from fasting triglycerides normal/borderline 
(,200 mg/day/L) to high ($200 mg/day/L) of 14.2% for 
patients receiving placebo compared with 11.9%, 10.8%, and 
11.8% of patients receiving modal doses of cariprazine 1.5–3, 
4.5–6, and 9–12 mg/day, respectively. Similarly, shift rates 
for total, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) cholesterol were not higher for cariprazine 
compared to placebo. Shift rates for fasting glucose normal 
(,100 mg/day/L) to high ($126 mg/day/L) were 6.7% for 
placebo compared with 7.4%, 9.8%, and 2.7% of patients 
receiving modal doses of cariprazine 1.5–3, 4.5–6, and 
9–12 mg/day, respectively, and thus did not follow a dose 
response. Difficult to interpret without more context is an 
absolute increase for fasting glucose $10 mg/day/L, found 
in 35.2%, 41.3%, 49.8%, and 50.3% of patients receiving 
placebo or modal doses of cariprazine 1.5–3, 4.5–6, and 
9–12 mg/day, respectively. As found in a large epidemiologi-
cal study, elevated fasting glucose level within the normal 
range can be an independent predictor of cardiovascular 
disease in men and of type 2 diabetes mellitus in both women 
and men.68
Table 2 is a list of spontaneously reported adverse events 
associated with the use of cariprazine (incidence $5% in 
any single cariprazine modal dose group and cariprazine 
incidence greater than placebo) observed in acute trials in 
schizophrenia and reported in product labeling10 and the pub-
lished pooled analysis,24 together with their respective values 
for NNH vs placebo. As per the product label, the most 
common adverse reactions (incidence $5% and double or 
more the rate of placebo) for patients with schizophrenia were 
EPS and akathisia. Within the dose range of 4.5–6 mg/day, 
NNH values vs placebo were as strong as 9 (95% CI 7–14) 
for EPS and 12 (95% CI 9–18) for akathisia. The product 
label notes that adverse events may first appear several weeks 
after the initiation of treatment, probably because plasma 
levels of cariprazine and its major metabolites accumulate 
over time.10
Published tolerability data focusing on only cariprazine 
1.5 mg/day are limited to one of the acute clinical trials.15 
Table 3 provides NNH values vs placebo for adverse events 
reported in that trial using two methods: comparison with 
the placebo group from that study alone and comparison 
with placebo groups pooled across the four acute studies.24 
In general, cariprazine 1.5 mg/day appears well tolerated. 
The strongest NNH values observed were for constipation 
when compared with placebo from the single study (NNH 16, 
95% CI 9–133) and akathisia when compared with placebo 
data pooled from all four available studies (NNH 19, 95% 
CI 10–209). The NNH value for akathisia for the 1.5 mg/day 
dose is about the same as for the 1.5–3 mg/day modal dose 
group (Table 2).
A meta-analysis is available of the tolerability and safety 
profile of cariprazine in the management of any mental dis-
order.62 Included in the meta-analysis are data from nine ran-
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the four acute studies in patients with schizophrenia,14–17 
the three pivotal studies for acute mania,53–55 and a study in 
bipolar depression,60 as well as a study in major depressive 
disorder,61 for a total of 4,324 subjects. Consistent with the 
data already presented for short-term studies in acute schizo-
phrenia, the risk of discontinuation due to adverse events for 
cariprazine was similar to that for placebo (RR 1.13, 95% CI 
0.77–1.66). Across all the studies, cariprazine was associ-
ated with higher risks of EPS-related events than placebo, 
including risk of akathisia (RR 3.92, 95% CI 2.83–5.43), 
tremor (RR 2.41, 95% CI 1.53–3.79), and restlessness (RR 
2.17, 95% CI 1.38–3.40). The cariprazine-treatment group 
was more likely to have clinically significant weight gain 
(RR 1.68, 95% CI 1.12–2.52), but no statistically significant 
differences in results were found in other metabolic param-
eters or cardiovascular-related events. There were no statisti-
cally significant effects on prolactin level.
Longer term safety
A single-arm, open-label, extension study evaluated the long-
term safety and tolerability of cariprazine 1.5–4.5 mg/day in 
93 patients with schizophrenia.21 Participants had completed 
the acute study that examined fixed doses of cariprazine 1.5, 
3, and 4.5 mg/day,15 and were also required to have responded 
to treatment (as defined by CGI-S #3 and $20% reduction 
in PANSS total score) in that study. Approximately 50% 
of patients completed the 48 weeks of open-label treat-
ment. Cariprazine 4.5 mg/day was the final dose for 70% of 
patients and was also the modal dose in 67.7%; 24.7% and 
7.5% of patients had modal daily doses of 3 and 1.5 mg/day, 
respectively. Common adverse events included were akath-
isia (14%), insomnia (14%), and weight increase (12%); 11% 
discontinued due to adverse events, none being akathisia or 
weight gain, and one patient discontinued because of insom-
nia. Mean changes in metabolic parameters were generally 
small and not clinically relevant. No patients shifted from 
normal/borderline levels of total or LDL cholesterol to high 
levels. Shifts from normal HDL-cholesterol levels to low 
levels occurred in about 23% of patients. About 14% of 
patients shifted from normal/borderline to high levels of 
triglycerides and about 4% with normal fasting glucose levels 
at baseline shifted to high levels. About 29% of patients had 
an increase in fasting glucose $10 mg/day/L. Mean body 
weight increased by 1.9 kg from the start of the lead-in study 
to the end of the extension study. Potentially clinically sig-
nificant weight gain ($7% increase from lead-in baseline) 
was experienced by 33% of patients, and 5% experienced 
weight increase $15%. Most patients who experienced $7% 
weight increase were normal or underweight at baseline. 
There were no discontinuations associated with change in 
metabolic parameters or body weight. Prolactin elevation or 
clinically significant changes in cardiovascular parameters 
were not observed. No patient had a QTc increase $60 ms 
or a postbaseline value .500 ms. There were no clinically 
significant changes in ophthalmologic parameters, including 
intraocular pressure, color discrimination, visual acuity, or 
lens opacity. An adverse event of cataract was noted; how-
ever, this resolved during the study, was not felt to represent 
an actual pathological event, and was likely due to variability 
on the part of the examiner.
Table 3 Potentially relevant adverse events associated with the use of cariprazine 1.5 mg/day as observed in Durgam et al15,a
Adverse event Cariprazine  
1.5 mg/day (n=145)
Placebo group15 (n=151) Pooled placebo group24 (n=584)
n (%) n (%) NNH (95% CI) n (%) NNH (95% CI)
extrapyramidal symptoms 13 (9.0) 7 (4.6) 24 (NS) 45 (7.7) 80 (NS)
Headache 16 (11.0) 16 (10.6) 229 (NS) 74 (12.7) NA
insomnia 15 (10.3) 11 (7.3) 33 (NS) 64 (11.0) NA
Somnolence or sedation 7 (4.8) 5 (3.3) 66 (NS) 32 (5.5) NA
Akathisia 13 (9.0) 7 (4.6) 24 (NS) 21 (3.6) 19 (10–209)
Constipation 14 (9.7) 5 (3.3) 16 (9–133) 29 (5.0) 22 (NS)
Nausea 7 (4.8) 5 (3.3) 66 (NS) 29 (5.0) NA
Anxiety 6 (4.1) 5 (3.3) 121 (NS) 24 (4.1) 3,529 (NS)
vomiting 4 (2.8) 5 (3.3) NA 20 (3.4) NA
Dizziness 5 (3.4) 3 (2.0) 69 (NS) 12 (2.1) 72 (NS)
weight increased 3 (2.1) 1 (0.7) 72 (NS) 8 (1.4) 143 (NS)
Note: aData for pooled placebo group was taken from earley et al24 and NNH values were calculated by the author.
Abbreviations: CI, confidence interval; NA, not applicable (adverse-event rate higher for placebo); NNH, number needed to harm; NS, not significant at the p,0.05 
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Cariprazine for the treatment of schizophrenia
A second open-label study evaluated the long-term safety 
and tolerability of cariprazine 3–9 mg/day in 586 patients 
with schizophrenia.22 Participants included both new patients 
(n=235) and patients who had completed one of the two 
phase III acute studies (n=351).16,17 Approximately 39% of 
patients completed the 48 weeks of open-label treatment. The 
most frequent modal daily dose was cariprazine 6 mg/day 
(50.9%), followed by 9 mg/day (25.3%) and 3 mg/day 
(22.9%). Common adverse events included were akath-
isia (16%), headache (13%), insomnia (13%), and weight 
increase (10%); 12.5% discontinued due to adverse events, 
with ,1% discontinuing due to akathisia. Mean cholesterol 
and triglyceride levels decreased; however, an increase of 
almost 5 mg/day/L in glucose was observed. Shifts from 
normal/borderline to high cholesterol levels were observed 
in about 5% of patients, shifts from normal/borderline to 
high LDL-cholesterol levels were observed in about 3% 
of patients, shifts from normal to low HDL-cholesterol 
levels were observed in about 12% of patients, shifts from 
normal/borderline to high triglyceride levels were observed 
in about 8% of patients, and for fasting glucose, shifts from 
normal/impaired to high levels were observed in about 6% 
of patients. Mean body weight increased by 1.5 kg from the 
start of the lead-in study to the end of the extension study. 
About 26% of patients had $7% increase from baseline in 
body weight, with patients categorized as underweight at 
baseline having the highest percentage of clinically signifi-
cant weight gain (40%).
Prolactin elevation or clinically significant changes in 
cardiovascular parameters were not observed. No retinal 
toxicity or cataracts were observed. One (0.2%) patient had a 
postbaseline QTcF value .500 ms, and three (0.5%) patients 
had QTcB postbaseline values .500 ms. An increase from 
baseline .60 ms in QTcF or QTcB values occurred in two 
(0.3%) and seven (1.2%) patients, respectively. Pooled data 
from both 48-week open-label safety studies21,22 are reported 
separately in a third publication.23 The pattern of results 
remain the same as described earlier.
Relapse prevention
A supplemental new-drug application for cariprazine for 
the maintenance treatment of adults with schizophrenia 
was approved by the FDA in November 2017,69 based 
on a placebo-controlled, randomized withdrawal study in 
nonelderly adult patients with schizophrenia.19,20 See also 
Table 4. To participate in the trial, patients were required to 
be acutely ill at screening. During the 20-week open-label 
treatment phase, patients received cariprazine 3–9 mg/day 
(starting at 1.5 mg/day on day 1). In order to be randomized 
to either continue cariprazine or to receive placebo, patients 
were required to meet prespecified stability criteria. Once ran-
domized, the double-blind phase consisted of 26–72 weeks 
of fixed-dose treatment. The primary efficacy outcome was 
time to first relapse during the double-blind phase. Relapse 
was defined as meeting any of several operational criteria 
(worsening of symptom scores, psychiatric hospitaliza-
tion, aggressive/violent behavior, or suicidal risk). A total 
of 264 patients of 765 (34.5%) completed the open-label 
phase, and 200 patients were randomized. Demographic 
and baseline characteristics of the participants entering the 
open-label phase were similar to those for the acute short-
term trials described earlier. Baseline PANSS score at the 
start of the double-blind phase was 51. At randomization, 
14 patients were taking cariprazine 3 mg/day, 37 patients 
were taking 6 mg/day, and 50 patients were taking 9 mg/
day. Based on Kaplan–Meier analysis, time to relapse was 
significantly longer for patients who continued cariprazine 
than for patients randomized to placebo (HR 0.45, 95% CI 
0.28–0.73). Observed relapse rates were 24.8% for caripra-
zine vs 47.5% for placebo, for a NNT of five (95% CI 3–11). 
The study protocol had the provision that subjects should 
meet the specified relapse criterion at a second assessment 
to be conducted 4–7 days after first meeting the criterion; 
however, the principal investigator had the discretion not 
to perform this second assessment based on safety reasons. 
Therefore, a sensitivity analysis that ensured that the first date 
of relapse was consistently applied was conducted in response 
to an FDA request,20 and the results of this are contained in 
product labeling10 (HR 0.52, 95% CI 0.33–0.82; Figure 2). 
Revised observed relapse rates were 29.7% for cariprazine vs 
49.5% for placebo, for a NNT of six (95% CI 3–16). These 
NNT values are similar to what has been reported for other 
first-line second-generation antipsychotics.70
As reported in the original analysis,19 the 25th percentile 
for time to relapse was 92 days in the placebo group and 224 
days in the cariprazine group. The 50th percentile (median) 
was 296 days for the placebo group and could not be calcu-
lated for the cariprazine group, because of the low number 
of relapse events. Of note, between-group separation of the 
curves did not occur until around day 50, possibly because of 
the long half-life of cariprazine (and specifically DDCAR), 
lending some extended protection against the risk of relapse, 
similar to what was observed when examining this phenom-
enon in similarly designed randomized-withdrawal studies 
conducted for paliperidone extended release oral vs 1-month 
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Cariprazine for the treatment of schizophrenia
The most commonly observed adverse events during the 
open-label phase were akathisia (19%), insomnia (14%), and 
headache (12%). During open-label treatment, akathisia and 
other EPS adverse events (excluding akathisia or restlessness) 
each led to discontinuation in ~1% of patients, while no EPS-
related adverse events led to discontinuation during double-
blind treatment. Changes from baseline in lipid parameters 
at the end of open-label and double-blind treatment were 
generally not clinically relevant. There were no clinically 
relevant mean changes in blood pressure, and no patient had 
a QTc of .500 ms. Weight gain $7% was reported in 11% 
of open-label patients, and in 32% of placebo-treated patients 
and 27% of cariprazine-treated patients during double-blind 
treatment.
Negative symptoms
Cariprazine’s European product label, the summary of prod-
uct characteristics,72 includes support for cariprazine’s effi-
cacy for the treatment of predominantly negative symptoms 
in patients with schizophrenia based on a 26-week double-
blind randomized study comparing cariprazine 4.5 mg/day 
with risperidone 4 mg/day in 460 nonelderly adult patients.27 
See also Table 4. There was no placebo control. In this study, 
patients were required to have a PANSS negative-factor 
score73 (NFS) $24, with single-item scores of at least mod-
erate on selected symptoms, such as blunted affect, passive/
apathetic social withdrawal, and lack of spontaneity and 
flow of conversation. Excluded were patients with a hospital 
admission or an acute exacerbation of schizophrenia within 
the last 6 months prior to the study, a PANSS positive-factor 
score .19, significant positive- or negative-symptom fluctua-
tions (ie, instability) during the prospective lead-in period, 
treatment with clozapine in the 12 months prior to the study, 
moderate–severe depressive symptoms, clinically relevant 
parkinsonian symptoms, or treatment with antidepressant 
medications and/or anticholinergic medications used to 
treat abnormal movements. After randomization, patients 
were uptitrated in 2 weeks to the target dose of cariprazine 
4.5 mg/day or risperidone 4 mg/day, but at the end of week 3 
and at every subsequent visit, the dose of the double-blind 
study medication could be decreased to 3 mg/day in cases of 
poor tolerability. In cases of impending psychotic deteriora-
tion, the dose could be increased to 6 mg/day.
Mean age was 40 years, and 57% of patients were male. 
Overall, 77% of patients completed the double-blind treat-
ment period. The mean daily dose for cariprazine was 4.2 mg 
and that for risperidone 3.8 mg. The modal dose (excluding 
the uptitration period) was the target dose (ie, 4.5 mg/day 
Figure 2 Kaplan–Meier curves of cumulative rate of relapse during the double-blind treatment period.
Notes: Reproduced from the product label.10 Although the study permitted dosing of cariprazine at 3–9 mg/day, the maximum recommended daily dose is 6 mg. Between-
group separation of the curves did not occur until around day 50, possibly because of the long half-life of cariprazine (and specifically DDCAR) lending some extended 
protection against the risk of relapse.
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for cariprazine and 4 mg/day for risperidone) for 95% of 
patients treated with either antipsychotic. Cariprazine was 
superior to risperidone on both the primary (PANSS-NFS) 
and key secondary outcomes (Personal and Social Perfor-
mance Scale). PANSS-NFS responder rates at week 26 (as 
defined by $20% decrease in baseline score) were 69% 
for cariprazine vs 58% for risperidone, resulting in a NNT 
of nine (95% CI 5–44). For outcome variables analyzed 
to assess pseudospecific effects (change from baseline for 
PANSS positive symptoms, depression, and parkinsonian 
symptoms), changes were small and similar for cariprazine 
and risperidone. These results thus excluded indirect effects 
related to positive, depressive, or EPS improvement as a 
factor in negative-symptom improvement. Quality-adjusted 
life-year gain was also modeled, and resulted in an estimated 
quality-adjusted life-year gain of 0.029 per patient after 
1 year of treatment.28 The most common adverse event for 
cariprazine was akathisia (8%), which was also observed for 
5% of persons randomized to risperidone.
Conclusion
Cariprazine is notable for being a dopamine-receptor partial 





receptors;10,13,30 this differs from other available antipsychot-
ics, and has theoretical advantages in people with schizo-
phrenia based on preclinical data. This is also supported by 
a single study27 demonstrating superiority over risperidone 
in the treatment of predominantly negative symptoms in 
patients with schizophrenia; however, the effect size was 
small and the study requires replication. Cariprazine is also 
approved in the US for the acute treatment of manic or mixed 
episodes associated with bipolar I disorder in adults.10,26,53–59 
An active clinical development plan includes studies in bipo-
lar I depression60 and major depressive disorder.61
Cariprazine also differs from other oral antipsychotics in 
terms of the extended half-life of its major active metabolite – 
DDCAR.10,18 DDCAR is the predominant circulating moiety, 
representing about 70% of the total exposure. An extended 
half-life carries important implications for dosing, as rapid 
increases in dose may be premature and possibly result in 
poorer tolerability. A long half-life also makes the interpre-
tation of the short-term acute trials more difficult, as steady 
state is not reached for some time and changes in dose will 
not be fully reflected in plasma for several weeks.10 However, 
a long half-life may provide a degree of protection when 
doses are occasionally missed. In the randomized-withdrawal 
relapse study,19 between-group separation of the curves did 
not occur until around day 50. Of note, cariprazine is the 
only antipsychotic with instructions allowing dosing every 
other day (1.5 mg/day for coadministration with a CYP3A4 
inhibitor). Under usual circumstances for patients with 
schizophrenia, the recommended dose range is 1.5–6 mg 
once daily, with a starting dose of 1.5 mg once daily with or 
without food. The product label does not provide guidance 
as to a preferred time of day when cariprazine should be 
administered. As described in detail earlier, the maximum 
Table 5 NNH vs placebo for approved first-line oral second-generation antipsychotics in adults, as observed in acute short-term 
studies for schizophreniaa














Cariprazine (to 6 mg/day) 34 3 100b 1 15 8 4.0
Brexpiprazole 17 7 50b 2 112 3 4.0
Aripiprazole 21 5 20c 4 25 7 5.3
Risperidone (to 8 mg/day) 18c 6 13 8 15 8 4.7
Olanzapine 6c 10 7c 11 25 7 9.3
Quetiapine immediate release 6 10 10c 10 NA 1 7.0
Quetiapine extended release 22 4 7 11 188 2 5.7
Ziprasidone 16 8 15 7 100 4 6.3
Paliperidone 35 2 42 3 39 5 3.3
iloperidone 10 9 16 6 NA 1 5.3
Asenapine 35 2 17 5 34 6 4.3
Lurasidone 67 1 11 9 10 9 6.3
Notes: aTable adapted (NNH values extracted),11 with permission; bsomnolence, sedation, hypersomnia; creported in product labeling for schizophrenia and bipolar mania 
pooled together.
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Cariprazine for the treatment of schizophrenia
recommended daily dose is 6 mg based on observations made 
during the short-term controlled trials, where dosages .6 mg 
daily did not confer increased effectiveness sufficient to 
outweigh dose-related adverse reactions.
Overall tolerability is promising, with the rate of discon-
tinuation due to adverse events lower than that observed for 
placebo in the acute trials for schizophrenia.14–17,24 Elevations 
in prolactin were not observed, and no clinically relevant 
effects on the electrocardiographic QT interval were evident. 
As with all second-generation antipsychotics, monitoring 
individual patients for alterations in weight and metabolic 
shifts is necessary.74 Using data from prior analyses,8,11 
Table 5 provides ranking of NNH values for clinically 
relevant weight gain, adverse events of somnolence, and 
adverse events of akathisia vs placebo for all first-line 
second-generation oral antipsychotics, as observed in short-
term studies in adults for schizophrenia and calculated from 
product labeling. Except for akathisia, cariprazine appears 
to have favorable (ie, higher) NNH values than some of the 
other agents. Of interest are the NNH values for somnolence, 
where cariprazine appears best in class with a ranking of 1. 
When contrasting the three available dopamine-receptor 
partial agonists, the order of propensity for weight gain 
appears to be brexpiprazole . aripiprazole . cariprazine, 
propensity for somnolence aripiprazole . brexpiprazole 
. cariprazine, and propensity for akathisia cariprazine . 
aripiprazole . brexpiprazole. These indirect comparisons 
will need to be confirmed by appropriately designed head-
to-head clinical trials.8 The averages of the ranking values 
are also shown (lower numbers are best) and give an idea of 
overall tolerability for each antipsychotic. Although most of 
the antipsychotics have similar average ranking values, an 
individual patient’s concerns for each of the different toler-
ability items would likely influence the choices considered 
acceptable, and in any event weighed against efficacy con-
siderations for that individual patient.3 An additional caveat 
is that the adverse-event rates reported here do not take into 
account severity or duration of the event: short-lived and 
perhaps easily manageable adverse events will be less likely 
problematic than adverse events such as weight gain, which 
can be persistent and more difficult to ameliorate. Another 
caveat is that adverse-event rates, and thus the NNH values 
derived from them, can vary by therapeutic indication.75,76
In general, despite the availability of many antipsychotics 
for the treatment of schizophrenia, this disorder is complex 
and often difficult to treat. As noted, antipsychotics vary 
in terms of tolerability and safety concerns,2 and patients 
themselves differ in terms of preexisting risk factors and 
comorbidities, which make drug selection challenging.5,77 
Having an additional choice is welcome.
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